Press releases - GSK
WEBGSK receives US FDA Breakthrough Therapy Designation for its B7-H3-targeted antibody-drug conjugate in relapsed or refractory extensive-stage small-cell lung cancer.
Press releases | GSK US
WEBUS FDA expands Jemperli (dostarlimab-gxly) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer as the first and only immuno-oncology-based treatment to show an overall survival benefit. Jemperli approval now includes MMRp/MSS tumors, which represent majority of endometrial cancer cases.
GSK's experimental drug shows promise in reducing severe …
WEBMay 21 (Reuters) - GSK's (GSK.L) experimental drug met its primary goal of reducing asthma attacks in a late-stage trial, marking a bright spot for a treatment that the British drugmaker expects to...
GSK delivers strong 2023 performance and upgrades growth …
WEBJan 31, 2024 · Broad-based performance drives sales, profits and earnings growth: Total 2023 sales £30.3 billion +5% and +14% ex COVID. Vaccines sales +25%, +24% ex COVID. Shingrix £3.4 billion +17%, Arexvy £1.2 billion.
GSK completes acquisition of Aiolos Bio for up to $1.4 bln
WEBLONDON, Feb 15 (Reuters) - GSK (GSK.L) said on Thursday it had completed the acquisition of Aiolos Bio, a clinical-stage biopharmaceutical company focused on respiratory and inflammatory...
GSK (LSE:GSK) Poised for Growth with Strong Sales, Strategic …
WEB4 days ago · GSK(LSE:GSK) is navigating a dynamic environment marked by both opportunities and challenges. Recent highlights include a robust 13% sales growth and strategic innovations in R&D, contrasted with ...
US FDA approves GSK’s AREXVY, the world’s first respiratory …
WEBMay 3, 2023 · GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved AREXVY (respiratory syncytial virus vaccine, adjuvanted) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. This is the first RSV vaccine for older ...
GSK News
WEBStay updated on the latest news from GSK, a global healthcare company with innovative medicines, vaccines and consumer products.
GSK Raises Outlook, Looks to New Medicines to Fuel Growth
WEBJul 26, 2023 · GSK Plc raised its guidance for the year after a strong start to 2023 as it prepares to begin selling one of the first vaccines to prevent a common respiratory virus.
Jemperli (dostarlimab-gxly) plus chemotherapy approved in the …
WEBJul 31, 2023 · GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) in combination with carboplatin and paclitaxel, followed by Jemperli as a single agent for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR), ...
Skip to content